Skip to main content
. 2010 Jul 29;15(8):799–809. doi: 10.1634/theoncologist.2009-0029

Figure 3.

Figure 3.

Kaplan–Meier plot comparing OS data from patients who continued trastuzumab beyond progression with that of patients who stopped trastuzumab treatment at or prior to progression from initiation of trastuzumab (A) and date of progression (B).

Abbreviations: CI, confidence interval; OS, overall survival.